Diligence memo · auto-generated · as of July 3, 2026
Manzara Therapeutics, Inc.
Manzara Therapeutics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Manzara Therapeutics, Inc. operates in Pharma, based in NEW YORK.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Manzara Therapeutics, Inc. has raised $750K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $750K on 2018-11-07.
Most recent recorded round closed around 2018-11-07.
Valuation (modeled)modeled
Provath models Manzara Therapeutics, Inc. at approximately $35M (range $420K–$402M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.51× the median modeled value of Pre-Seed Pharma companies in 2016–2018 (20 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 7.6 yr ago; this sector typically re-raises about every 16 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 32% of Pharma peers (310 compared).
Modeled value ranks above 51% of those peers.
Closest niche peers: vivo-TIL Therapeutics, Inc, JSK Therapeutics, Inc., Kyto Biopharma Inc, Mirata BioPharma, LLC, Avery Therapeutics, Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.